본문 바로가기
KERD
논문KCI 등재

Analysis of Once-Daily Thoracic Radiotherapy Dose According to the Underlying Lung Disease in Patients with Limited-Stage Small Cell Lung Cancer Undergoing Concurrent Chemoradiotherapy

김학재|김수지|정주현|우홍균|김병혁|손재만
대한암학회 (Korean Cancer Association)|2023.01|Cancer Research and Treatment|제55권 제1호|pp. 73-82|DOI 10.4143/crt.2021.1202

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

RadiotherapySmall-cell lung carcinomaUnderlying lung disease
주제분류의학일반

초록

Purpose In the treatment of concurrent chemoradiotherapy (CCRT) in limited-stage small cell lung cancer, the optimal once-daily radiotherapy (RT) dose/fractionation remain unclear although it is the most frequently used. Therefore, this study aimed to compare the treatment outcomes and toxicities of modest dose RT (≤ 54 Gy) with those of standard dose RT (> 54 Gy) and investigate the benefit of the high dose based on patient factors.Materials and Methods Since 2004, our institution has gradually increased the thoracic RT dose. Among the 225 patients who underwent CCRT, 84 patients (37.3%) received > 54 Gy. Because the patients treated with RT > 54 Gy were not randomly assigned, propensity score matching (PSM) was performed.Results The proportion of patients treated with > 54 Gy increased over time (p=0.014). Multivariate analysis revealed that the overall tumor stage and dose > 54 Gy (hazard ratio, 0.65; p=0.029) were independent prognostic factors for overall survival (OS). PSM confirmed that thoracic RT doses of > 54 Gy showed significantly improved progression-free survival (3-year, 42.7% vs. 24.0%; p < 0.001) and OS (3-year, 56.2% vs. 38.5%; p=0.003). Sensitivity analysis also showed that 60 Gy resulted in better survival than 54 Gy. However, in patients with underlying lung disease, OS benefit from > 54 Gy was not observed but considerable rates of severe pulmonary toxicities were observed (p=0.001).Conclusion Our analysis supports that the 60 Gy RT dose should be considered in the once-daily regimen of CCRT for limited-stage small cell lung cancer without underlying lung disease, but RT dose > 54 Gy did not seem to benefit for patients with chronic obstructive pulmonary disease or interstitial lung disease. Further study is needed to validate these results.

Abstract

Purpose In the treatment of concurrent chemoradiotherapy (CCRT) in limited-stage small cell lung cancer, the optimal once-daily radiotherapy (RT) dose/fractionation remain unclear although it is the most frequently used. Therefore, this study aimed to compare the treatment outcomes and toxicities of modest dose RT (≤ 54 Gy) with those of standard dose RT (> 54 Gy) and investigate the benefit of the high dose based on patient factors.Materials and Methods Since 2004, our institution has gradually increased the thoracic RT dose. Among the 225 patients who underwent CCRT, 84 patients (37.3%) received > 54 Gy. Because the patients treated with RT > 54 Gy were not randomly assigned, propensity score matching (PSM) was performed.Results The proportion of patients treated with > 54 Gy increased over time (p=0.014). Multivariate analysis revealed that the overall tumor stage and dose > 54 Gy (hazard ratio, 0.65; p=0.029) were independent prognostic factors for overall survival (OS). PSM confirmed that thoracic RT doses of > 54 Gy showed significantly improved progression-free survival (3-year, 42.7% vs. 24.0%; p < 0.001) and OS (3-year, 56.2% vs. 38.5%; p=0.003). Sensitivity analysis also showed that 60 Gy resulted in better survival than 54 Gy. However, in patients with underlying lung disease, OS benefit from > 54 Gy was not observed but considerable rates of severe pulmonary toxicities were observed (p=0.001).Conclusion Our analysis supports that the 60 Gy RT dose should be considered in the once-daily regimen of CCRT for limited-stage small cell lung cancer without underlying lung disease, but RT dose > 54 Gy did not seem to benefit for patients with chronic obstructive pulmonary disease or interstitial lung disease. Further study is needed to validate these results.

참고문헌 (24)

  1. Turrisi AT 3rd, "Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide", N Engl J Med, 340, pp.265~271 (1999)
  2. Schreiber D, "Utilization of hyperfractionated radiation in small-cell lung cancer and its impact on survival", J Thorac Oncol, 10, pp.1770~1775 (2015)
  3. Farrell MJ, "Radiation dose and fractionation for limitedstage small-cell lung cancer : survey of US radiation oncologists on practice patterns", Clin Lung Cancer, 20, pp.13~19 (2019)
  4. Faivre-Finn C, "Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer(CONVERT) : an open-label, phase 3, randomised, superiority trial", Lancet Oncol, 18, pp.1116~1125 (2017)
  5. Bogart JA, "Phase 3 comparison of high-dose once-daily(QD)thoracic radiotherapy(TRT)with standard twice-daily(BID)TRT in limited stage small cell lung cancer(LSCLC) : CALGB 30610(Alliance)", RTOG 0538, 2021, pp.39(15 Suppl), 8505~
  6. Daly ME, "Radiation therapy for small-cell lung cancer : ASCO guideline endorsement of an ASTRO guideline", J Clin Oncol, 39, pp.931~939 (2021)
  7. Stinchcombe TE, "A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients", Cancer, 125, pp.382~390 (2019)
  8. Kobayashi H, "Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities", Radiat Oncol, 16, pp.52~ (2021)
  9. Han TJ, "Comparison of treatment outcomes between involved-field and elective nodal irradiation in limited-stage small cell lung cancer", Jpn J Clin Oncol, 42, pp.948~954 (2012)
  10. Cox JD, "Toxicity criteria of the Radiation Therapy Oncology Group(RTOG)and the European Organization for Research and Treatment of Cancer(EORTC)", Int J Radiat Oncol Biol Phys, 31, pp.1341~1346 (1995)
  11. Li F, "Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy", Radiat Oncol, 13, pp.82~ (2018)
  12. Song MJ, "Prognosis of small cell lung cancer with idiopathic pulmonary fibrosis : assessment according to GAP stage", J Oncol, 2019, pp.5437390~ (2019)
  13. Kim K, "Treatment outcomes of limited-stage small cell lung cancer patients treated with concurrent chemoradiation therapy : a comparative analysis of different radiation dose fractionation schedules in a single institution", Int J Radiat Oncol, 90(1Suppl), pp.S632~ (2014)
  14. Han D, "Comparison of once daily radiotherapy to 60 Gy and twice daily radiotherapy to 45 Gy for limited stage small-cell lung cancer", Thorac Cancer, 6, pp.643~648 (2015)
  15. Watkins JM, "Once-daily radiotherapy to > or =59. 4 Gy versus twice-daily radiotherapy to > or =45. 0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer : a comparative analysis of toxicities and outcomes", Jpn J Radiol, 28, pp.340~348 (2010)
  16. Gazula A, "Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer", Lung, 192, pp.151~158 (2014)
  17. Tomita N, "The impact of radiation dose and fractionation on outcomes for limited-stage small-cell lung cancer", Int J Radiat Oncol Biol Phys, 76, pp.1121~1126 (2010)
  18. Bogart J, "Interim toxicity analysis for patients with limited stage small cell lung cancer(LSCLC)treated on the experimental thoracic radiotherapy(TRT)arms of CALGB 30610(Alliance)", RTOG 0538, 2019, pp.30, v711~
  19. Bogart JA, "Short communication : interim toxicity analysis for patients with limited stage small cell lung cancer(LSCLC)treated on CALGB 30610(Alliance)", RTOG 0538, 2021, pp.156, 68~71
  20. Gronberg BH, "High-dose versus standarddose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer : an open-label, randomised, phase 2 trial", Lancet Oncol, 22, pp.321~331 (2021)
  21. Bradley JD, "Long-term results of NRG oncology RTOG 0617 : standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer", J Clin Oncol, 38, pp.706~714 (2020)
  22. Komaki R, "Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer : report of Radiation Therapy Oncology Group(RTOG)protocol 97-12", Int J Radiat Oncol Biol Phys, 62, pp.342~350 (2005)
  23. Rutter CE, "Comparison of survival outcomes among standard radiotherapy regimens in limited-stage small cell lung cancer patients receiving concurrent chemoradiation", Lung Cancer, 90, pp.243~248 (2015)
  24. Zayed S, "Is there a role for hypofractionated thoracic radiation therapy in limited-stage small cell lung cancer? A propensity score matched analysis", Int J Radiat Oncol Biol Phys, 108, pp.575~586 (2020)

이 간행물의 다른 논문 (31건)

Oligometastasis: More Lessons to Be Learned김경환, 안용찬pp. 1-4Top Ten Lessons Learned from Trials in Oligometastatic CancersVivian S. Tan, David A. Palmapp. 5-14Adherence to Cancer Prevention Guidelines and Cancer Incidence and Mortality: A Population-Based Cohort Study박은영, 한민지, 오진경, 김병미pp. 15-27Interlaboratory Comparison Study (Ring Test) of Next-Generation Sequencing–Based NTRK Fusion Detection in South Korea최윤라, 강준, 이승은, 심효섭, 전윤경, 이미숙, 김지훈pp. 28-40Suggestions for Escaping the Dark Ages for Pediatric Diffuse Intrinsic Pontine Glioma Treated with Radiotherapy: Analysis of Prognostic Factors from the National Multicenter Study정재욱, 이주호, 김인아, 김영경, 임정호, 박신형, 김주영, 윤홍인, 서창옥, 안승도, 김일한, 임도훈, 김현주pp. 41-49
원문 보기